Broad targeting of resistance to apoptosis in cancer

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages S78-S103

  Mohammad, Ramzi M ^a,b   Muqbil, Irfana ^a   Lowe, Leroy ^c   Yedjou, Clement ^d   Hsu, Hsue Yin ^e   Lin, Liang Tzung ^f   Siegelin, Markus David ^g   Fimognari, Carmela ^h   Kumar, Nagi B ⁱ   Dou, Q Ping ^a,j   Yang, Huanjie ^k   Samadi, Abbas K ^l   Russo, Gian Luigi ^m   Spagnuolo, Carmela ^m   Ray, Swapan K ⁿ   Chakrabarti, Mrinmay ⁿ   Morre, James D ^o   Coley, Helen M ^p   Honoki, Kanya ^q   Fujii, Hiromasa ^q   Georgakilas, Alexandros G ^r   Amedei, Amedeo ^s   Niccolai, Elena ^s   Amin, Amr ^t,u   Ashraf, S Salman ^t   Helferich, William G ^v   Yang, Xujuan ^v   Boosani, Chandra S ^w   Guha, Gunjan ^x   Bhakta, Dipita ^x   Ciriolo, Maria Rosa ^y   Aquilano, Katia ^y   Chen, Sophie ^z   Mohammed, Sulma I ^aa   Keith, W Nicol ^ab   Bilsland, Alan ^ab   Halicka, Dorota ^ac   Nowsheen, Somaira ^ad   Azmi, Asfar S ^a   more..

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HAMAD MEDICAL CORPORATION   (Qatar)

^c Getting to Know Cancer   (Canada)

^d Jackson State University   (United States)

^e TZU CHI UNIVERSITY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NewYork Presbyterian Hospital   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j KARMANOS CANCER INSTITUTE   (United States)

^k HARBIN INSTITUTE OF TECHNOLOGY   (China)

^l Sanus Biosciences   (United States)

^m CNR   (Italy)

ⁿ UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^o PURDUE UNIVERSITY   (United States)

^p UNIVERSITY OF SURREY   (United Kingdom)

^q NARA MEDICAL UNIVERSITY   (Japan)

^r NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^s UNIVERSITY OF FLORENCE   (Italy)

^t UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^u CAIRO UNIVERSITY   (Egypt)

^v UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^w CREIGHTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^x SASTRA UNIVERSITY   (India)

^y UNIVERSITY OF ROME TOR VERGATA   (Italy)

^z Ovarian and Prostate Cancer Research Trust Laboratory   (United Kingdom)

^aa PURDUE UNIVERSITY   (United States)

^ab UNIVERSITY OF GLASGOW   (United Kingdom)

^ac NEW YORK MEDICAL COLLEGE   (United States)

^ad MAYO CLINIC   (United States)

more..

Author keywords

Apoptosis; Apoptosis evasion; Autophagy; Necrosis; Nuclear transporters, natural chemopreventive agents

Indexed keywords

ANTINEOPLASTIC AGENT; CURCUMIN; EPIGALLOCATECHIN GALLATE; GOSSYPOL; HEAT SHOCK PROTEIN 90; ISOTHIOCYANIC ACID DERIVATIVE; PLANT MEDICINAL PRODUCT; PROTEASOME; PROTEIN BCL 2; PROTEIN MCL 1; QUERCETIN; RESVERATROL; SELINEXOR; TRIPTOLIDE; UMI 77; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; AUTOPHAGY; BREAST CANCER; CELL COMPARTMENTALIZATION; CELL DEATH; CELL TRANSPORT; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DRUG POTENTIATION; DRUG TARGETING; EPIGENETICS; GENOMIC INSTABILITY; GLIOBLASTOMA; HUMAN; MELANOMA; METASTASIS; NECROPTOSIS; NONHUMAN; NUCLEAR EXPORT SIGNAL; PANCREAS ADENOCARCINOMA; PLEIOTROPY; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR PROMOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AUTOPHAGY; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84928539179     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.03.001     Document Type: Review

References (497)

1. Vogelstein B., Papadopoulos N., Velculescu V.E., Zhou S., Diaz L.A., Kinzler K.W. Cancer genome landscapes. Science 2013, 339:1546-1558.
2. Ringash J., Au H.J., Siu L.L., Shapiro J.D., Jonker D.J., Zalcberg J.R., et al. Quality of life in patients with K-RAS wild-type colorectal cancer: the CO.20 phase 3 randomized trial. Cancer 2014, 120:181-189.
3. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
4. Du T.A. Cell death: balance through a bivalent regulator. Nat Rev Mol Cell Biol 2013, 14:546.
5. Korsmeyer S.J., Shutter J.R., Veis D.J., Merry D.E., Oltvai Z.N. Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol 1993, 4:327-332.
6. Morin P.J. Drug resistance and the microenvironment: nature and nurture. Drug Resist Updat 2003, 6:169-172.
7. Baguley B.C. Multiple drug resistance mechanisms in cancer. Mol Biotechnol 2010, 46:308-316.
8. Ferguson L.R., Baguley B.C. Multidrug resistance and mutagenesis. Mutat Res 1993, 285:79-90.
9. Baguley B.C. Multidrug resistance in cancer. Methods Mol Biol 2010, 596:1-14.
10. Masood A., Azmi A.S., Mohammad R.M. Small molecule inhibitors of bcl-2 family proteins for pancreatic cancer therapy. Cancers (Basel) 2011, 3:1527-1549.
11. Czabotar P.E., Lessene G., Strasser A., Adams J.M. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 2013, 15:49-63.
12. Vitagliano O., Addeo R., D'Angelo V., Indolfi C., Indolfi P., Casale F. The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches. Expert Rev Hematol 2013, 6:587-597.
13. Mortenson M.M., Galante J.G., Gilad O., Schlieman M.G., Virudachalam S., Kung H.J., et al. BCL-2 functions as an activator of the AKT signaling pathway in pancreatic cancer. J Cell Biochem 2007, 102:1171-1179.
14. Kumar P., Ning Y., Polverini P.J. Endothelial cells expressing Bcl-2 promotes tumor metastasis by enhancing tumor angiogenesis, blood vessel leakiness and tumor invasion. Lab Investig: J Techn Methods Pathol 2008, 88:740-749.
15. Tucker C.A., Kapanen A.I., Chikh G., Hoffman B.G., Kyle A.H., Wilson I.M., et al. Silencing Bcl-2 in models of mantle cell lymphoma is associated with decreases in cyclin D1, nuclear factor-kappaB, p53, bax, and p27 levels. Mol Cancer Ther 2008, 7:749-758.
16. Anai S., Shiverick K., Medrano T., Nakamura K., Goodison S., Brown B.D., et al. Downregulation of BCL-2 induces downregulation of carbonic anhydrase IX, vascular endothelial growth factor, and pAkt and induces radiation sensitization. Urology 2007, 70:832-837.
17. Patel M.P., Masood A., Patel P.S., Chanan-Khan A.A. Targeting the Bcl-2. Curr Opin Oncol 2009, 21:516-523.
18. Wang J.Y. Nucleo-cytoplasmic communication in apoptotic response to genotoxic and inflammatory stress. Cell Res 2005, 15:43-48.
19. Ewen C.L., Kane K.P., Bleackley R.C. A quarter century of granzymes. Cell Death Differ 2012, 19:28-35.
20. Lord S.J., Rajotte R.V., Korbutt G.S., Bleackley R.C. Granzyme B: a natural born killer. Immunol Rev 2003, 193:31-38.
21. Chowdhury D., Beresford P.J., Zhu P., Zhang D., Sung J.S., Demple B., et al. The exonuclease TREX1 is in the SET complex and acts in concert with NM23-H1 to degrade DNA during granzyme A-mediated cell death. Mol Cell 2006, 23:133-142.
22. Yuan S., Akey C.W. Apoptosome structure, assembly, and procaspase activation. Structure 2013, 21:501-515.
23. Azmi A.S., Mohammad R.M. Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 2009, 218:13-21.
24. Azmi A.S., Wang Z., Philip P.A., Mohammad R.M., Sarkar F.H. Emerging Bcl-2 inhibitors for the treatment of cancer. Expert Opin Emerg Drugs 2011, 16:59-70.
25. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 2009, 66:1326-1336.
26. Warr M.R., Shore G.C. Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med 2008, 8:138-147.
27. Quinn B.A., Dash R., Azab B., Sarkar S., Das S.K., Kumar S., et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011, 20:1397-1411.
28. Karami H., Baradaran B., Esfehani A., Sakhinia M., Sakhinia E. Down-regulation of Mcl-1 by small interference RNA induces apoptosis and sensitizes HL-60 leukemia cells to etoposide. Asian Pac J Cancer Prev 2014, 15:629-635.
29. Chen L., Willis S.N., Wei A., Smith B.J., Fletcher J.I., Hinds M.G., et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005, 17:393-403.
30. Yecies D., Carlson N.E., Deng J., Letai A. Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 2010, 115:3304-3313.
31. Lestini B.J., Goldsmith K.C., Fluchel M.N., Liu X., Chen N.L., Goyal B., et al. Mcl1 downregulation sensitizes neuroblastoma to cytotoxic chemotherapy and small molecule Bcl2-family antagonists. Cancer Biol Ther 2009, 8:1587-1595.
32. Abulwerdi F., Liao C., Liu M., Azmi A.S., Aboukameel A., Mady A.S., et al. A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther 2014, 13:565-575.
33. Basu A., Bodycombe N.E., Cheah J.H., Price E.V., Liu K., Schaefer G.I., et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell 2013, 154:1151-1161.
34. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
35. Gandhi L., Camidge D.R., Ribeiro de O.M., Bonomi P., Gandara D., Khaira D., et al. Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 2011, 29:909-916.
36. Souers A.J., Leverson J.D., Boghaert E.R., Ackler S.L., Catron N.D., Chen J., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19:202-208.
37. Rosenbluh J., Nijhawan D., Cox A.G., Li X., Neal J.T., Schafer E.J., et al. beta-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell 2012, 151:1457-1473.
38. Mathew R., Karantza-Wadsworth V., White E. Role of autophagy in cancer. Nat Rev Cancer 2007, 7:961-967.
39. Liu D., Yang Y., Liu Q., Wang J. Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol 2011, 28:105-111.
40. Xi G., Hu X., Wu B., Jiang H., Young C.Y., Pang Y., et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett 2011, 307:141-148.
41. Sharma N., Thomas S., Golden E.B., Hofman F.M., Chen T.C., Petasis N.A., et al. Inhibition of autophagy and induction of breast cancer cell death by mefloquine, an antimalarial agent. Cancer Lett 2012, 326:143-154.
42. Carew J.S., Nawrocki S.T., Giles F.J., Cleveland J.L. Targeting autophagy: a novel anticancer strategy with therapeutic implications for imatinib resistance. Biologics 2008, 2:201-204.
43. Carew J.S., Medina E.C., Esquivel J.A., Mahalingam D., Swords R., Kelly K., et al. Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation. J Cell Mol Med 2010, 14:2448-2459.
44. Carew J.S., Kelly K.R., Nawrocki S.T. Autophagy as a target for cancer therapy: new developments. Cancer Manag Res 2012, 4:357-365.
45. Dupere-Richer D., Kinal M., Menasche V., Nielsen T.H., Del R.S., Pettersson F., et al. Vorinostat-induced autophagy switches from a death-promoting to a cytoprotective signal to drive acquired resistance. Cell Death Dis 2013, 4:e486.
46. Xu N., Zhang J., Shen C., Luo Y., Xia L., Xue F., et al. Cisplatin-induced downregulation of miR-199a-5p increases drug resistance by activating autophagy in HCC cell. Biochem Biophys Res Commun 2012, 423:826-831.
47. Wang S.Y., Yu Q.J., Zhang R.D., Liu B. Core signaling pathways of survival/death in autophagy-related cancer networks. Int J Biochem Cell Biol 2011, 43:1263-1266.
48. Maiuri M.C., Zalckvar E., Kimchi A., Kroemer G. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007, 8:741-752.
49. Li X., Wu W.K., Sun B., Cui M., Liu S., Gao J., et al. Dihydroptychantol A, a macrocyclic bisbibenzyl derivative, induces autophagy and following apoptosis associated with p53 pathway in human osteosarcoma U2OS cells. Toxicol Appl Pharmacol 2011, 251:146-154.
50. Wang W., Fan H., Zhou Y., Duan P., Zhao G., Wu G. Knockdown of autophagy-related gene BECLIN1 promotes cell growth and inhibits apoptosis in the A549 human lung cancer cell line. Mol Med Rep 2013, 7:1501-1505.
51. Yu L., Alva A., Su H., Dutt P., Freundt E., Welsh S., et al. Regulation of an ATG7-beclin 1 program of autophagic cell death by caspase-8. Science 2004, 304:1500-1502.
52. Pan X., Zhang X., Sun H., Zhang J., Yan M., Zhang H. Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS ONE 2013, 8:e56679.
53. Salminen A., Kaarniranta K., Kauppinen A. Beclin 1 interactome controls the crosstalk between apoptosis, autophagy and inflammasome activation: impact on the aging process. Ageing Res Rev 2013, 12:520-534.
54. He C., Wei Y., Sun K., Li B., Dong X., Zou Z., et al. Beclin 2 functions in autophagy, degradation of G protein-coupled receptors, and metabolism. Cell 2013, 154:1085-1099.
55. Marquez R.T., Xu L. Bcl-2:Beclin 1 complex: multiple, mechanisms regulating autophagy/apoptosis toggle switch. Am J Cancer Res 2012, 2:214-221.
56. Tai W.T., Shiau C.W., Chen H.L., Liu C.Y., Lin C.S., Cheng A.L., et al. Mcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells. Cell Death Dis 2013, 4:e485.
57. Cheng P., Ni Z., Dai X., Wang B., Ding W., Rae S.A., et al. The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma [corrected] cells. Cell Death Dis 2013, 4:e489.
58. Pomerantz J., Schreiber-Agus N., Liegeois N.J., Silverman A., Alland L., Chin L., et al. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92:713-723.
59. Sherr C.J., Weber J.D. The ARF/p53 pathway. Curr Opin Genet Dev 2000, 10:94-99.
60. Reef S., Zalckvar E., Shifman O., Bialik S., Sabanay H., Oren M., et al. A short mitochondrial form of p19ARF induces autophagy and caspase-independent cell death. Mol Cell 2006, 22:463-475.
61. Balaburski G.M., Hontz R.D., Murphy M.E. p53 and ARF: unexpected players in autophagy. Trends Cell Biol 2010, 20:363-369.
62. Gozuacik D. Identification of human cancer-related genes by naturally occurring Hepatitis B Virus DNA tagging. Oncogene 2001, 20:6233-6240.
63. Kondo Y., Kanzawa T., Sawaya R., Kondo S. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005, 5:726-734.
64. Pimkina J., Murphy M.E. Interaction of the ARF tumor suppressor with cytosolic HSP70 contributes to its autophagy function. Cancer Biol Ther 2011, 12:503-509.
65. Christophorou M.A., Ringshausen I., Finch A.J., Swigart L.B., Evan G.I. The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature 2006, 443:214-217.
66. Junttila M.R., Karnezis A.N., Garcia D., Madriles F., Kortlever R.M., Rostker F., et al. Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 2010, 468:567-571.
67. Dewaele M., Maes H., Agostinis P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010, 6:838-854.
68. Nicolau-Galmes F., Asumendi A., onso-Tejerina E., Perez-Yarza G., Jangi S.M., Gardeazabal J., et al. Terfenadine induces apoptosis and autophagy in melanoma cells through ROS-dependent and -independent mechanisms. Apoptosis 2011, 16:1253-1267.
69. Chen Y., Azad M.B., Gibson S.B. Superoxide is the major reactive oxygen species regulating autophagy. Cell Death Differ 2009, 16:1040-1052.
70. Scherz-Shouval R., Shvets E., Fass E., Shorer H., Gil L., Elazar Z. Reactive oxygen species are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 2007, 26:1749-1760.
71. Mathew R., Kongara S., Beaudoin B., Karp C.M., Bray K., Degenhardt K., et al. Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev 2007, 21:1367-1381.
72. Azad M.B., Chen Y., Henson E.S., Cizeau J., Millan-Ward E., Israels S.J., et al. Hypoxia induces autophagic cell death in apoptosis-competent cells through a mechanism involving BNIP3. Autophagy 2008, 4:195-204.
73. Shi Y., Tang B., Yu P.W., Tang B., Hao Y.X., Lei X., et al. Autophagy protects against oxaliplatin-induced cell death via ER stress and ROS in Caco-2 cells. PLoS ONE 2012, 7:e51076.
74. Boldogh I., Roy G., Lee M.S., Bacsi A., Hazra T.K., Bhakat K.K., et al. Reduced DNA double strand breaks in chlorambucil resistant cells are related to high DNA-PKcs activity and low oxidative stress. Toxicology 2003, 193:137-152.
75. Huang Q., Wu Y.T., Tan H.L., Ong C.N., Shen H.M. A novel function of poly(ADP-ribose) polymerase-1 in modulation of autophagy and necrosis under oxidative stress. Cell Death Differ 2009, 16:264-277.
76. Munoz-Gamez J.A., Rodriguez-Vargas J.M., Quiles-Perez R., guilar-Quesada R., Martin-Oliva D., de M.G., et al. PARP-1 is involved in autophagy induced by DNA damage. Autophagy 2009, 5:61-74.
77. Wyllie A.H. Death from inside out: an overview. Philos Trans R Soc Lond B: Biol Sci 1994, 345:237-241.
78. Giampietri C., Starace D., Petrungaro S., Filippini A., Ziparo E. Necroptosis: molecular signalling and translational implications. Int J Cell Biol 2014, 2014:490275.
79. Van C.S., Van den B.W. Morphological and biochemical aspects of apoptosis, oncosis and necrosis. Anat Histol Embryol 2002, 31:214-223.
80. Walker N.I., Harmon B.V., Gobe G.C., Kerr J.F. Patterns of cell death. Methods Achiev Exp Pathol 1988, 13:18-54.
81. Murdoch W.J., Wilken C., Young D.A. Sequence of apoptosis and inflammatory necrosis within the formative ovulatory site of sheep follicles. J Reprod Fertil 1999, 117:325-329.
82. Murdoch W.J. Plasmin-tumour necrosis factor interaction in the ovulatory process. J Reprod Fertil Suppl 1999, 54:353-358.
83. Jaattela M., Tschopp J. Caspase-independent cell death in T lymphocytes. Nat Immunol 2003, 4:416-423.
84. Roach H.I., Clarke N.M. Physiological cell death of chondrocytes in vivo is not confined to apoptosis. New observations on the mammalian growth plate. J Bone Joint Surg Br 2000, 82:601-613.
85. Barkla D.H., Gibson P.R. The fate of epithelial cells in the human large intestine. Pathology 1999, 31:230-238.
86. Chautan M., Chazal G., Cecconi F., Gruss P., Golstein P. Interdigital cell death can occur through a necrotic and caspase-independent pathway. Curr Biol 1999, 9:967-970.
87. Lenardo M.J., Angleman S.B., Bounkeua V., Dimas J., Duvall M.G., Graubard M.B., et al. Cytopathic killing of peripheral blood CD4(+) T lymphocytes by human immunodeficiency virus type 1 appears necrotic rather than apoptotic and does not require env. J Virol 2002, 76:5082-5093.
88. Brennan M.A., Cookson B.T. Salmonella induces macrophage death by caspase-1-dependent necrosis. Mol Microbiol 2000, 38:31-40.
89. Cho Y., McQuade T., Zhang H., Zhang J., Chan F.K. RIP1-dependent and independent effects of necrostatin-1 in necrosis and T cell activation. PLoS ONE 2011, 6:e23209.
90. Marubayashi S., Koppikar P., Taldone T., bdel-Wahab O., West N., Bhagwat N., et al. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest 2010, 120:3578-3593.
91. Shimamura T., Lowell A.M., Engelman J.A., Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res 2005, 65:6401-6408.
92. Shimamura T., Li D., Ji H., Haringsma H.J., Liniker E., Borgman C.L., et al. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res 2008, 68:5827-5838.
93. Shimamura T., Perera S.A., Foley K.P., Sang J., Rodig S.J., Inoue T., et al. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res 2012, 18:4973-4985.
94. Socinski M.A., Goldman J., El-Hariry I., Koczywas M., Vukovic V., Horn L., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013, 19:3068-3077.
95. Kang B.H., Plescia J., Dohi T., Rosa J., Doxsey S.J., Altieri D.C. Regulation of tumor cell mitochondrial homeostasis by an organelle-specific Hsp90 chaperone network. Cell 2007, 131:257-270.
96. Masuda Y., Shima G., Aiuchi T., Horie M., Hori K., Nakajo S., et al. Involvement of tumor necrosis factor receptor-associated protein 1 (TRAP1) in apoptosis induced by beta-hydroxyisovalerylshikonin. J Biol Chem 2004, 279:42503-42515.
97. Fortugno P., Beltrami E., Plescia J., Fontana J., Pradhan D., Marchisio P.C., et al. Regulation of survivin function by Hsp90. Proc Natl Acad Sci USA 2003, 100:13791-13796.
98. Gyurkocza B., Plescia J., Raskett C.M., Garlick D.S., Lowry P.A., Carter B.Z., et al. Antileukemic activity of shepherdin and molecular diversity of hsp90 inhibitors. J Natl Cancer Inst 2006, 98:1068-1077.
99. Kang B.H., Plescia J., Song H.Y., Meli M., Colombo G., Beebe K., et al. Combinatorial drug design targeting multiple cancer signaling networks controlled by mitochondrial Hsp90. J Clin Invest 2009, 119:454-464.
100. Siegelin M.D. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer. Cancer Lett 2013, 333:133-146.
101. Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005, 6:79-87.
102. Kisselev A.F., Songyang Z., Goldberg A.L. Why does threonine, and not serine, function as the active site nucleophile in proteasomes. J Biol Chem 2000, 275:14831-14837.
103. Moore B.S., Eustaquio A.S., McGlinchey R.P. Advances in and applications of proteasome inhibitors. Curr Opin Chem Biol 2008, 12:434-440.
104. Borissenko L., Groll M. 20S proteasome and its inhibitors: crystallographic knowledge for drug development. Chem Rev 2007, 107:687-717.
105. Jesenberger V., Jentsch S. Deadly encounter: ubiquitin meets apoptosis. Nat Rev Mol Cell Biol 2002, 3:112-121.
106. Voorhees P.M., Orlowski R.Z. The proteasome and proteasome inhibitors in cancer therapy. Annu Rev Pharmacol Toxicol 2006, 46:189-213.
107. Richardson P.G., Hideshima T., Anderson K.C. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers. Cancer Control 2003, 10:361-369.
108. Chen S., Fribley A., Wang C.Y. Potentiation of tumor necrosis factor-mediated apoptosis of oral squamous cell carcinoma cells by adenovirus-mediated gene transfer of NF-kappaB inhibitor. J Dent Res 2002, 81:98-102.
109. Ghosh S., Karin M. Missing pieces in the NF-kappaB puzzle. Cell 2002, 109(Suppl):S81-S96.
110. Jentsch S. Ubiquitin-dependent protein degradation: a cellular perspective. Trends Cell Biol 1992, 2:98-103.
111. An B., Goldfarb R.H., Siman R., Dou Q.P. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5:1062-1075.
112. Li B., Dou Q.P. Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc Natl Acad Sci USA 2000, 97:3850-3855.
113. Dimmeler S., Breitschopf K., Haendeler J., Zeiher A.M. Dephosphorylation targets Bcl-2 for ubiquitin-dependent degradation: a link between the apoptosome and the proteasome pathway. J Exp Med 1999, 189:1815-1822.
114. Glasspool R.M., Teodoridis J.M., Brown R. Epigenetics as a mechanism driving polygenic clinical drug resistance. Br J Cancer 2006, 94:1087-1092.
115. Ajabnoor G.M., Crook T., Coley H.M. Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis 2012, 3:e260.
116. Syed N., Coley H.M., Sehouli J., Koensgen D., Mustea A., Szlosarek P., et al. Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer. Cancer Res 2011, 71:3317-3327.
117. Bredberg A., Bodmer W. Cytostatic drug treatment causes seeding of gene promoter methylation. Eur J Cancer 2007, 43:947-954.
118. Matthew E.M., Hart L.S., Astrinidis A., Navaraj A., Dolloff N.G., Dicker D.T., et al. The p53 target Plk2 interacts with TSC proteins impacting mTOR signaling, tumor growth and chemosensitivity under hypoxic conditions. Cell Cycle (Georgetown, Tex) 2009, 8:4168-4175.
119. Coley H.M., Safuwan N.A., Chivers P., Papacharalbous E., Giannopoulos T., Butler-Manuel S., et al. The cyclin-dependent kinase inhibitor p57(Kip2) is epigenetically regulated in carboplatin resistance and results in collateral sensitivity to the CDK inhibitor seliciclib in ovarian cancer. Br J Cancer 2012, 106:482-489.
120. Lee M.P., Feinberg A.P. Aberrant splicing but not mutations of TSG101 in human breast cancer. Cancer Res 1997, 57:3131-3134.
121. Fischer D.C., Noack K., Runnebaum I.B., Watermann D.O., Kieback D.G., Stamm S., et al. Expression of splicing factors in human ovarian cancer. Oncol Rep 2004, 11:1085-1090.
122. Piekielko-Witkowska A., Wiszomirska H., Wojcicka A., Poplawski P., Boguslawska J., Tanski Z., et al. Disturbed expression of splicing factors in renal cancer affects alternative splicing of apoptosis regulators, oncogenes, and tumor suppressors. PLoS ONE 2010, 5:e13690.
123. Karni R., de S.E., Lowe S.W., Sinha R., Mu D., Krainer A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol Biol 2007, 14:185-193.
124. Merdzhanova G., Edmond V., De S.S., Van den B.A., Corcos L., Brambilla C., et al. E2F1 controls alternative splicing pattern of genes involved in apoptosis through upregulation of the splicing factor SC35. Cell Death Differ 2008, 15:1815-1823.
125. Edmond V., Brambilla C., Brambilla E., Gazzeri S., Eymin B. SRSF2 is required for sodium butyrate-mediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines. Cell Cycle (Georgetown, Tex) 2011, 10:1968-1977.
126. Edmond V., Moysan E., Khochbin S., Matthias P., Brambilla C., Brambilla E., et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 2011, 30:510-523.
127. Diekmann Y., Pereira-Leal J.B. Evolution of intracellular compartmentalization. Biochem J 2013, 449:319-331.
128. Van B.K., Corces V.G. Nuclear organization and genome function. Annu Rev Cell Dev Biol 2012, 28:163-187.
129. Schneider R., Grosschedl R. Dynamics and interplay of nuclear architecture, genome organization, and gene expression. Genes Dev 2007, 21:3027-3043.
130. Nagano A., Arahata K. Nuclear envelope proteins and associated diseases. Curr Opin Neurol 2000, 13:533-539.
131. Raices M., D'Angelo M.A. Nuclear pore complex composition: a new regulator of tissue-specific and developmental functions. Nat Rev Mol Cell Biol 2012, 13:687-699.
132. Grossman E., Medalia O., Zwerger M. Functional architecture of the nuclear pore complex. Annu Rev Biophys 2012, 41:557-584.
133. Oeffinger M., Zenklusen D. To the pore and through the pore: a story of mRNA export kinetics. Biochim Biophys Acta 2012, 1819:494-506.
134. Walde S., Kehlenbach R.H. The part and the whole: functions of nucleoporins in nucleocytoplasmic transport. Trends Cell Biol 2010, 20:461-469.
135. Xu D., Farmer A., Chook Y.M. Recognition of nuclear targeting signals by Karyopherin-beta proteins. Curr Opin Struct Biol 2010, 20:782-790.
136. Chook Y.M., Suel K.E. Nuclear import by karyopherin-betas: recognition and inhibition. Biochim Biophys Acta 2011, 1813:1593-1606.
137. Fornerod M., Ohno M. Exportin-mediated nuclear export of proteins and ribonucleoproteins. Results Probl Cell Differ 2002, 35:67-91.
138. Marelli M., Dilworth D.J., Wozniak R.W., Aitchison J.D. The dynamics of karyopherin-mediated nuclear transport. Biochem Cell Biol 2001, 79:603-612.
139. Yoneda Y. Nuclear pore-targeting complex and its role on nuclear protein transport. Arch Histol Cytol 1996, 59:97-107.
140. Marfori M., Lonhienne T.G., Forwood J.K., Kobe B. Structural basis of high-affinity nuclear localization signal interactions with importin-alpha. Traffic 2012, 13:532-548.
141. van der Watt P.J., Maske C.P., Hendricks D.T., Parker M.I., Denny L., Govender D., et al. The Karyopherin proteins, Crm1 and Karyopherin beta1, are overexpressed in cervical cancer and are critical for cancer cell survival and proliferation. Int J Cancer 2009, 124:1829-1840.
142. Hutten S., Kehlenbach R.H. CRM1-mediated nuclear export: to the pore and beyond. Trends Cell Biol 2007, 17:193-201.
143. Fukuda M., Asano S., Nakamura T., Adachi M., Yoshida M., Yanagida M., et al. CRM1 is responsible for intracellular transport mediated by the nuclear export signal. Nature 1997, 390:308-311.
144. Shaulsky G., Goldfinger N., Tosky M.S., Levine A.J., Rotter V. Nuclear localization is essential for the activity of p53 protein. Oncogene 1991, 6:2055-2065.
145. Turner J.G., Sullivan D.M. CRM1-mediated nuclear export of proteins and drug resistance in cancer. Curr Med Chem 2008, 15:2648-2655.
146. Huang W.Y., Yue L., Qiu W.S., Wang L.W., Zhou X.H., Sun Y.J. Prognostic value of CRM1 in pancreas cancer. Clin Invest Med 2009, 32:E315.
147. Wang Z., Li Y., Ahmad A., Banerjee S., Azmi A.S., Kong D., et al. Pancreatic cancer: understanding and overcoming chemoresistance. Nat Rev Gastroenterol Hepatol 2011, 8:27-33.
148. Mao L., Yang Y. Targeting the nuclear transport machinery by rational drug design. Curr Pharm Des 2013, 19:2318-2325.
149. Yashiroda Y., Yoshida M. Nucleo-cytoplasmic transport of proteins as a target for therapeutic drugs. Curr Med Chem 2003, 10:741-748.
150. Hamamoto T., Seto H., Beppu T. Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation. J Antibiot (Tokyo) 1983, 36:646-650.
151. Hamamoto T., Gunji S., Tsuji H., Beppu T. Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterization. J Antibiot (Tokyo) 1983, 36:639-645.
152. Kudo N., Matsumori N., Taoka H., Fujiwara D., Schreiner E.P., Wolff B., et al. Leptomycin B inactivates CRM1/exportin 1 by covalent modification at a cysteine residue in the central conserved region. Proc Natl Acad Sci USA 1999, 96:9112-9117.
153. Newlands E.S., Rustin G.J., Phase Brampton M.H. I trial of elactocin. Br J Cancer 1996, 74:648-649.
154. Sakakibara K., Saito N., Sato T., Suzuki A., Hasegawa Y., Friedman J.M., et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood 2011, 118:3922-3931.
155. Kalid O., Toledo W.D., Shechter S., Sherman W., Shacham S. Consensus Induced Fit Docking (cIFD): methodology, validation, and application to the discovery of novel Crm1 inhibitors. J Comput Aided Mol Des 2012, 26:1217-1228.
156. Inoue H., Kauffman M., Shacham S., Landesman Y., Yang J., Evans C.P., et al. CRM1 blockade by selective inhibitors of nuclear export (SINE) attenuates kidney cancer growth. J Urol 2013, 189:2317-2326.
157. Etchin J., Sun Q., Kentsis A., Farmer A., Zhang Z.C., Sanda T., et al. Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells. Leukemia 2013, 27:66-74.
158. Zhang K., Wang M., Tamayo A.T., Shacham S., Kauffman M., Lee J., et al. Novel selective inhibitors of nuclear export CRM1 antagonists for therapy in mantle cell lymphoma. Exp Hematol 2013, 41:67-78.
159. Azmi A.S., Al-Katib A., Aboukameel A., McCauley D., Kauffman M., Shacham S., et al. Selective inhibitors of nuclear export for the treatment of non-Hodgkin's Lymphomas. Haematologica 2013, 98:1098-1106.
160. Azmi A.S., Aboukameel A., Bao B., Sarkar F.H., Philip P.A., Kauffman M., et al. Selective inhibitors of nuclear export block pancreatic cancer cell proliferation and reduce tumor growth in mice. Gastroenterology 2012, 144:447-456.
161. Mutka S.C., Yang W.Q., Dong S.D., Ward S.L., Craig D.A., Timmermans P.B., et al. Identification of nuclear export inhibitors with potent anticancer activity in vivo. Cancer Res 2009, 69:510-517.
162. Muqbil I., Bao B., bou-Samra A.B., Mohammad R.M., Azmi A.S. Nuclear export mediated regulation of microRNAs: potential target for drug intervention. Curr Drug Targets 2013, 14:1094-1100.
163. Azmi A.S. Unveiling the role of nuclear transport in epithelial-to-mesenchymal transition. Curr Cancer Drug Targets 2013, 13:906-914.
164. Robert M., Wastie M. Glioblastoma multiforme: a rare manifestation of extensive liver and bone metastases. Biomed Imaging Interv J 2008, 4:e3.
165. Dreyfuss J.M., Johnson M.D., Park P.J. Meta-analysis of glioblastoma multiforme versus anaplastic astrocytoma identifies robust gene markers. Mol Cancer 2009, 8:71.
166. Brandes A.A., Franceschi E., Tosoni A., Benevento F., Scopece L., Mazzocchi V., et al. Temozolomide concomitant and adjuvant to radiotherapy in elderly patients with glioblastoma: correlation with MGMT promoter methylation status. Cancer 2009, 115:3512-3518.
167. Das A., Banik N.L., Ray S.K. Modulatory effects of acetazolomide and dexamethasone on temozolomide-mediated apoptosis in human glioblastoma T98G and U87MG cells. Cancer Invest 2008, 26:352-358.
168. Lai A., Tran A., Nghiemphu P.L., Pope W.B., Solis O.E., Selch M., et al. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol 2011, 29:142-148.
169. Grossman S.A., Ye X., Piantadosi S., Desideri S., Nabors L.B., Rosenfeld M., et al. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 2010, 16:2443-2449.
170. Spiegl-Kreinecker S., Pirker C., Filipits M., Lotsch D., Buchroithner J., Pichler J., et al. O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. Neuro Oncol 2010, 12:28-36.
171. Krakstad C., Chekenya M. Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 2010, 9:135.
172. Haas-Kogan D.A., Prados M.D., Tihan T., Eberhard D.A., Jelluma N., Arvold N.D., et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 2005, 97:880-887.
173. Brem S., Tsanaclis A.M., Gately S., Gross J.L., Herblin W.F. Immunolocalization of basic fibroblast growth factor to the microvasculature of human brain tumors. Cancer 1992, 70:2673-2680.
174. Chakravarti A., Loeffler J.S., Dyson N.J. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002, 62:200-207.
175. Stommel J.M., Kimmelman A.C., Ying H., Nabioullin R., Ponugoti A.H., Wiedemeyer R., et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007, 318:287-290.
176. Huang T.T., Sarkaria S.M., Cloughesy T.F., Mischel P.S. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics 2009, 6:500-512.
177. Hirose Y., Berger M.S., Pieper R.O. p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 2001, 61:1957-1963.
178. Vogler M., Dinsdale D., Dyer M.J., Cohen G.M. Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 2009, 16:360-367.
179. Tagscherer K.E., Fassl A., Campos B., Farhadi M., Kraemer A., Bock B.C., et al. Apoptosis-based treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008, 27:6646-6656.
180. Manero F., Gautier F., Gallenne T., Cauquil N., Gree D., Cartron P.F., et al. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 2006, 66:2757-2764.
181. Bushunow P., Reidenberg M.M., Wasenko J., Winfield J., Lorenzo B., Lemke S., et al. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 1999, 43:79-86.
182. Wang G., Nikolovska-Coleska Z., Yang C.Y., Wang R., Tang G., Guo J., et al. Structure-based design of potent small-molecule inhibitors of anti-apoptotic Bcl-2 proteins. J Med Chem 2006, 49:6139-6142.
183. Dodou K., Anderson R.J., Small D.A., Groundwater P.W. Investigations on gossypol: past and present developments. Expert Opin Investig Drugs 2005, 14:1419-1434.
184. Srinivasula S.M., Ashwell J.D. IAPs: what's in a name. Mol Cell 2008, 30:123-135.
185. George J., Banik N.L., Ray S.K. Survivin knockdown and concurrent 4-HPR treatment controlled human glioblastoma in vitro and in vivo. Neuro Oncol 2010, 12:1088-1101.
186. Karmakar S., Banik N.L., Ray S.K. Combination of all-trans retinoic acid and paclitaxel-induced differentiation and apoptosis in human glioblastoma U87MG xenografts in nude mice. Cancer 2008, 112:596-607.
187. Das A., Banik N.L., Ray S.K. Retinoids induced astrocytic differentiation with down regulation of telomerase activity and enhanced sensitivity to taxol for apoptosis in human glioblastoma T98G and U87MG cells. J Neurooncol 2008, 87:9-22.
188. Lacasse E.C., Mahoney D.J., Cheung H.H., Plenchette S., Baird S., Korneluk R.G. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
189. Joo K.M., Kim S.Y., Jin X., Song S.Y., Kong D.S., Lee J.I., et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Investig: J Techn Methods Pathol 2008, 88:808-815.
190. Vellanki S.H., Grabrucker A., Liebau S., Proepper C., Eramo A., Braun V., et al. Small-molecule XIAP inhibitors enhance gamma-irradiation-induced apoptosis in glioblastoma. Neoplasia 2009, 11:743-752.
191. Fulda S., Wick W., Weller M., Debatin K.M. Smac agonists sensitize for Apo2L/T. Nat Med 2002, 8:808-815.
192. Singh S.K., Morbach H., Nanki T., Girschick H.J. Differential expression of chemokines in synovial cells exposed to different Borrelia burgdorferi isolates. Clin Exp Rheumatol 2005, 23:311-322.
193. Richmond A., Lawson D.H., Nixon D.W., Chawla R.K. Characterization of autostimulatory and transforming growth factors from human melanoma cells. Cancer Res 1985, 45:6390-6394.
194. Mrowietz U., Schwenk U., Maune S., Bartels J., Kupper M., Fichtner I., et al. The chemokine RANTES is secreted by human melanoma cells and is associated with enhanced tumour formation in nude mice. Br J Cancer 1999, 79:1025-1031.
195. Bottazzi B., Walter S., Govoni D., Colotta F., Mantovani A. Monocyte chemotactic cytokine gene transfer modulates macrophage infiltration, growth, and susceptibility to IL-2 therapy of a murine melanoma. J Immunol 1992, 148:1280-1285.
196. Lowman H.B., Slagle P.H., DeForge L.E., Wirth C.M., Gillece-Castro B.L., Bourell J.H., et al. Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities. J Biol Chem 1996, 271:14344-14352.
197. Bernard D., Quatannens B., Vandenbunder B., Abbadie C. Rel/NF-kappaB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J Biol Chem 2001, 276:27322-27328.
198. Oya M., Ohtsubo M., Takayanagi A., Tachibana M., Shimizu N., Murai M. Constitutive activation of nuclear factor-kappaB prevents TRAIL-induced apoptosis in renal cancer cells. Oncogene 2001, 20:3888-3896.
199. Sato T., Irie S., Kitada S., Reed J.C. FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411-415.
200. Ivanov V.N., Lopez B.P., Maulit G., Sato T.A., Sassoon D., Ronai Z. FAP-1 association with Fas (Apo-1) inhibits Fas expression on the cell surface. Mol Cell Biol 2003, 23:3623-3635.
201. Deveraux Q.L., Roy N., Stennicke H.R., Van A.T., Zhou Q., Srinivasula S.M., et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998, 17:2215-2223.
202. Deveraux Q.L., Takahashi R., Salvesen G.S., Reed J.C. X-linked IAP is a direct inhibitor of cell-death proteases. Nature 1997, 388:300-304.
203. Kraehn G.M., Utikal J., Udart M., Greulich K.M., Bezold G., Kaskel P., et al. Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases. Br J Cancer 2001, 84:72-79.
204. Hinz M., Gottschling D., Eritja R., Seliger H. Synthesis and properties of 2'-deoxycytidine triphosphate carrying c-myc tag sequence. Nucleosides Nucleotides Nucleic Acids 2000, 19:1543-1552.
205. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
206. Beeram M., Patnaik A., Rowinsky E.K. Regulation of c-Raf-1: therapeutic implications. Clin Adv Hematol Oncol 2003, 1:476-481.
207. Beeram M., Patnaik A., Rowinsky E.K. Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 2005, 23:6771-6790.
208. Gray-Schopfer V.C., da Rocha D.S., Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 2005, 24:165-183.
209. Gray-Schopfer V., Wellbrock C., Marais R. Melanoma biology and new targeted therapy. Nature 2007, 445:851-857.
210. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62:10-29.
211. Kitano H. Cancer robustness: tumour tactics. Nature 2003, 426:125.
212. Haugk B. Pancreatic intraepithelial neoplasia - can we detect early pancreatic cancer. Histopathology 2010, 57:503-514.
213. Mihaljevic A.L., Michalski C.W., Friess H., Kleeff J. Molecular mechanism of pancreatic cancer - understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg 2010, 395:295-308.
214. Sheikh R., Walsh N., Clynes M., O'Connor R., McDermott R. Challenges of drug resistance in the management of pancreatic cancer. Expert Rev Anticancer Ther 2010, 10:1647-1661.
215. Dangi-Garimella S., Krantz S.B., Shields M.A., Grippo P.J., Munshi H.G. Epithelial-mesenchymal transition and pancreatic cancer progression 2012.
216. Rasheed Z.A., Matsui W., Maitra A. Pathology of pancreatic stroma in PDAC 2012.
217. Wang Z., Azmi A.S., Ahmad A., Banerjee S., Wang S., Sarkar F.H., et al. TW-37, a small-molecule inhibitor of Bcl-2, inhibits cell growth and induces apoptosis in pancreatic cancer: involvement of Notch-1 signaling pathway. Cancer Res 2009, 69:2757-2765.
218. O'Connell J., Bennett M.W., Nally K., Houston A., O'Sullivan G.C., Shanahan F. Altered mechanisms of apoptosis in colon cancer: Fas resistance and counterattack in the tumor-immune conflict. Ann N Y Acad Sci 2000, 910:178-192.
219. Karantanos T., Evans C.P., Tombal B., Thompson T.C., Montironi R., Isaacs W.B. Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur Urol 2015, 67:470-479.
220. Berchem G.J., Bosseler M., Sugars L.Y., Voeller H.J., Zeitlin S., Gelmann E.P. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995, 55:735-738.
221. Bonkhoff H., Fixemer T., Remberger K. Relation between Bcl-2, cell proliferation, and the androgen receptor status in prostate tissue and precursors of prostate cancer. Prostate 1998, 34:251-258.
222. Balakumaran B.S., Herbert J.T., Febbo P.G. MYC activity mitigates response to rapamycin in prostate cancer through 4EBP1-mediated inhibition of autophagy. Autophagy 2010, 6:281-282.
223. Balakumaran B.S., Porrello A., Hsu D.S., Glover W., Foye A., Leung J.Y., et al. MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy. Cancer Res 2009, 69:7803-7810.
224. Chang P.C., Wang T.Y., Chang Y.T., Chu C.Y., Lee C.L., Hsu H.W., et al. Autophagy pathway is required for IL-6 induced neuroendocrine differentiation and chemoresistance of prostate cancer LNCaP cells. PLoS ONE 2014, 9:e88556.
225. Bennett H.L., Stockley J., Fleming J.T., Mandal R., O'Prey J., Ryan K.M., et al. Does androgen-ablation therapy (AAT) associated autophagy have a pro-survival effect in LNCaP human prostate cancer cells. BJU Int 2013, 111:672-682.
226. Ziparo E., Petrungaro S., Marini E.S., Starace D., Conti S., Facchiano A., et al. Autophagy in prostate cancer and androgen suppression therapy. Int J Mol Sci 2013, 14:12090-12106.
227. Giampietri C., Petrungaro S., Padula F., D'Alessio A., Marini E.S., Facchiano A., et al. Autophagy modulators sensitize prostate epithelial cancer cell lines to TNF-alpha-dependent apoptosis. Apoptosis 2012, 17:1210-1222.
228. Parrondo R., de Las P.A., Reiner T., Perez-Stable C. ABT-737, a small molecule Bcl-2/Bcl-xL antagonist, increases antimitotic-mediated apoptosis in human prostate cancer cells. Peer J 2013, 1:e144.
229. Zhang X.Q., Huang X.F., Hu X.B., Zhan Y.H., An Q.X., Yang S.M., et al. Apogossypolone, a novel inhibitor of antiapoptotic Bcl-2 family proteins, induces autophagy of PC-3 and LNCaP prostate cancer cells in vitro. Asian J Androl 2010, 12:697-708.
230. Jackson R.S., Placzek W., Fernandez A., Ziaee S., Chu C.Y., Wei J., et al. Sabutoclax, a Mcl-1 antagonist, inhibits tumorigenesis in transgenic mouse and human xenograft models of prostate cancer. Neoplasia 2012, 14:656-665.
231. Zheng L., Yang W., Zhang C., Ding W.J., Zhu H., Lin N.M., et al. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1. Cancer Lett 2011, 309:27-36.
232. Zhang C., Cai T.Y., Zhu H., Yang L.Q., Jiang H., Dong X.W., et al. Synergistic antitumor activity of gemcitabine and ABT-737 in vitro and in vivo through disrupting the interaction of USP9X and Mcl-1. Mol Cancer Ther 2011, 10:1264-1275.
233. Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 2011, 8:417-427.
234. Shin E.A., Sohn E.J., Won G., Choi J.U., Jeong M., Kim B., et al. Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis. Oncotarget 2014, 5:5624-5636.
235. Videira M., Reis R.L., Brito M.A. Deconstructing breast cancer cell biology and the mechanisms of multidrug resistance. Biochim Biophys Acta 2014, 1846:312-325.
236. Filipova A., Seifrtova M., Mokry J., Dvorak J., Rezacova M., Filip S., et al. Breast cancer and cancer stem cells: a mini-review. Tumori 2014, 100:363-369.
237. Booy E.P., Henson E.S., Gibson S.B. Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer. Oncogene 2011, 30:2367-2378.
238. Oakes S.R., Vaillant F., Lim E., Lee L., Breslin K., Feleppa F., et al. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 2012, 109:2766-2771.
239. Elfadl D., Hodgkinson V.C., Long E.D., Scaife L., Drew P.J., Lind M.J., et al. A pilot study to investigate the role of the 26S proteasome in radiotherapy resistance and loco-regional recurrence following breast conserving therapy for early breast cancer. Breast 2011, 20:334-337.
240. Panischeva L.A., Kakpakova E.S., Rybalkina E.Y., Stavrovskaya A.A. Influence of proteasome inhibitor bortezomib on the expression of multidrug resistance genes and Akt kinase activity. Biochemistry (Mosc) 2011, 76:1009-1016.
241. Caligaris-Cappio F. B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 1996, 87:2615-2620.
242. Damle R.N., Calissano C., Chiorazzi N. Chronic lymphocytic leukaemia: a disease of activated monoclonal B cells. Best Pract Res Clin Haematol 2010, 23:33-45.
243. Messmer B.T., Messmer D., Allen S.L., Kolitz J.E., Kudalkar P., Cesar D., et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005, 115:755-764.
244. Tinhofer I., Marschitz I., Kos M., Henn T., Egle A., Villunger A., et al. Differential sensitivity of CD4+ and CD8+ T lymphocytes to the killing efficacy of Fas (Apo-1/CD95) ligand+ tumor cells in B chronic lymphocytic leukemia. Blood 1998, 91:4273-4281.
245. Macfarlane M., Inoue S., Kohlhaas S.L., Majid A., Harper N., Kennedy D.B., et al. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 2005, 12:773-782.
246. Cory S., Adams J.M. The Bcl2 family: regulators of the cellular life-or-death switch. Nat Rev Cancer 2002, 2:647-656.
247. Buggins A.G., Pepper C.J. The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010, 34:837-842.
248. Pepper C., Hoy T., Bentley D.P. Bcl-2/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer 1997, 76:935-938.
249. Robertson L.E., Plunkett W., McConnell K., Keating M.J., McDonnell T.J. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 1996, 10:456-459.
250. Pepper C., Lin T.T., Pratt G., Hewamana S., Brennan P., Hiller L., et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008, 112:3807-3817.
251. Awan F.T., Kay N.E., Davis M.E., Wu W., Geyer S.M., Leung N., et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009, 113:535-537.
252. Veronese L., Tournilhac O., Verrelle P., Davi F., Dighiero G., Chautard E., et al. Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia. Leukemia 2008, 22:1291-1293.
253. Hallaert D.Y., Jaspers A., van Noesel C.J., van Oers M.H., Kater A.P., Eldering E. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches. Blood 2008, 112:5141-5149.
254. Smit L.A., Hallaert D.Y., Spijker R., de G.B., Jaspers A., Kater A.P., et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007, 109:1660-1668.
255. Longo P.G., Laurenti L., Gobessi S., Sica S., Leone G., Efremov D.G. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008, 111:846-855.
256. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
257. Qi X.J., Wildey G.M., Howe P.H. Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem 2006, 281:813-823.
258. Durig J., Duhrsen U., Klein-Hitpass L., Worm J., Hansen J.B., Orum H., et al. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia 2011, 25:638-647.
259. Billard C. Design of novel BH3 mimetics for the treatment of chronic lymphocytic leukemia. Leukemia 2012, 26:2032-2038.
260. Nana-Sinkam S.P., Croce C.M. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Genet Cytogenet 2010, 203:127-133.
261. Hallek M. Therapy of chronic lymphocytic leukaemia. Best Pract Res Clin Haematol 2010, 23:85-96.
262. Dighiero G., Hamblin T.J. Chronic lymphocytic leukaemia. Lancet 2008, 371:1017-1029.
263. Elter T., Gercheva-Kyuchukova L., Pylylpenko H., Robak T., Jaksic B., Rekhtman G., et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol 2011, 12:1204-1213.
264. bou-Nassar K., Brown J.R. Novel agents for the treatment of chronic lymphocytic leukemia. Clin Adv Hematol Oncol 2010, 8:886-895.
265. Balakrishnan K., Wierda W.G., Keating M.J., Gandhi V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood 2008, 112:1971-1980.
266. Balakrishnan K., Burger J.A., Wierda W.G., Gandhi V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood 2009, 113:149-153.
267. Etxebarria A., Landeta O., Antonsson B., Basanez G. Regulation of antiapoptotic MCL-1 function by gossypol: mechanistic insights from in vitro reconstituted systems. Biochem Pharmacol 2008, 76:1563-1576.
268. Russo M., Spagnuolo C., Tedesco I., Russo G.L. Phytochemicals in cancer prevention and therapy: truth or dare?. Toxins (Basel) 2010, 2:517-551.
269. Bruel A., Karsenty E., Schmid M., McDonnell T.J., Lanotte M. Altered sensitivity to retinoid-induced apoptosis associated with changes in the subcellular distribution of Bcl-2. Exp Cell Res 1997, 233:281-287.
270. Russo G.L., Russo M., Spagnuolo C., Tedesco I., Bilotto S., Iannitti R., et al. Quercetin: a pleiotropic kinase inhibitor against cancer. Cancer Treat Res 2014, 159:185-205.
271. Boots A.W., Haenen G.R., Bast A. Health effects of quercetin: from antioxidant to nutraceutical. Eur J Pharmacol 2008, 585:325-337.
272. Forman H.J., Davies K.J., Ursini F. How do nutritional antioxidants really work: nucleophilic tone and para-hormesis versus free radical scavenging in vivo. Free Radic Biol Med 2014, 66:24-35.
273. Gundala S.R., Yang C., Mukkavilli R., Paranjpe R., Brahmbhatt M., Pannu V., et al. Hydroxychavicol, a betel leaf component, inhibits prostate cancer through ROS-driven DNA damage and apoptosis. Toxicol Appl Pharmacol 2014, 280:86-96.
274. Singh T., Sharma S.D., Katiyar S.K. Grape proanthocyanidins induce apoptosis by loss of mitochondrial membrane potential of human non-small cell lung cancer cells in vitro and in vivo. PLoS ONE 2011, 6:e27444.
275. Shen M., Schmitt S., Buac D., Dou Q.P. Targeting the ubiquitin-proteasome system for cancer therapy. Expert Opin Ther Targets 2013, 17:1091-1108.
276. Kumar N., Crocker T., Smith T., Connors S., Pow-Sang J., Spiess P.E., et al. Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures. J Clin Trials 2012, 2.
277. Nam S., Smith D.M., Dou Q.P. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001, 276:13322-13330.
278. Le Y., Cui Y., Iribarren P., Ying G., Wang J.M. Manipulating chemoattractant and receptor genes. In Vivo (Athens, Greece) 2002, 16:1-23.
279. Kazi A., Wang Z., Kumar N., Falsetti S.C., Chan T.H., Dou Q.P. Structure-activity relationships of synthetic analogs of (-)-epigallocatechin-3-gallate as proteasome inhibitors. Anticancer Res 2004, 24:943-954.
280. Smith D.M., Wang Z., Kazi A., Li L.H., Chan T.H., Dou Q.P. Synthetic analogs of green tea polyphenols as proteasome inhibitors. Mol Med 2002, 8:382-392.
281. Adhami V.M., Ahmad N., Mukhtar H. Molecular targets for green tea in prostate cancer prevention. J Nutr 2003, 133. 2417S-24S.
282. Liang Y.C., Lin-Shiau S.Y., Chen C.F., Lin J.K. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell Biochem 1997, 67:55-65.
283. Chung J.Y., Huang C., Meng X., Dong Z., Yang C.S. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 1999, 59:4610-4617.
284. Liang Y.C., Lin-Shiau S.Y., Chen C.F., Lin J.K. Inhibition of cyclin-dependent kinases 2 and 4 activities as well as induction of Cdk inhibitors p21 and p27 during growth arrest of human breast carcinoma cells by (-)-epigallocatechin-3-gallate. J Cell Biochem 1999, 75:1-12.
285. Adhami V.M., Malik A., Zaman N., Sarfaraz S., Siddiqui I.A., Syed D.N., et al. Combined inhibitory effects of green tea polyphenols and selective cyclooxygenase-2 inhibitors on the growth of human prostate cancer cells both in vitro and in vivo. Clin Cancer Res 2007, 13:1611-1619.
286. Kazi A., Daniel K.G., Smith D.M., Kumar N.B., Dou Q.P. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol 2003, 66:965-976.
287. Kumar N., Chornokur G. Molecular targeted therapies using botanicals for prostate cancer chemoprevention. Transl Med (Sunnyvale) 2012, (Suppl. 2):005.
288. Shanafelt T.D., Call T.G., Zent C.S., Leis J.F., LaPlant B., Bowen D.A., et al. Phase 2 trial of daily, oral Polyphenon E in patients with asymptomatic, Rai stage 0 to II chronic lymphocytic leukemia. Cancer 2013, 119:363-370.
289. Shanafelt T.D., Call T.G., Zent C.S., LaPlant B., Bowen D.A., Roos M., et al. Phase I trial of daily oral Polyphenon E in patients with asymptomatic Rai stage 0 to II chronic lymphocytic leukemia. J Clin Oncol 2009, 27:3808-3814.
290. Lin T.S., Ruppert A.S., Johnson A.J., Fischer B., Heerema N.A., Andritsos L.A., et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009, 27:6012-6018.
291. Phelps M.A., Lin T.S., Johnson A.J., Hurh E., Rozewski D.M., Farley K.L., et al. Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia. Blood 2009, 113:2637-2645.
292. Molinari M., Watt K.D., Kruszyna T., Nelson R., Walsh M., Huang W.Y., et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 2006, 12:1892-1895.
293. Pedros C., Cereza G., Garcia N., Laporte J.R. Liver toxicity of Camellia sinensis dried etanolic extract. Med Clin (Barc) 2003, 121:598-599.
294. Tahmatzopoulos A., Gudegast C., Stockle M., Wullich B., Unteregger G., Zwergel U., et al. Proteasome inhibitors: induction of apoptosis as new therapeutic option in prostate cancer. Aktuelle Urol 2004, 35:491-496.
295. Papandreou C.N., Logothetis C.J. Bortezomib as a potential treatment for prostate cancer. Cancer Res 2004, 64:5036-5043.
296. Adams J., Kauffman M. Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest 2004, 22:304-311.
297. Chow H.H., Cai Y., Hakim I.A., Crowell J.A., Shahi F., Brooks C.A., et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003, 9:3312-3319.
298. Mozzicafreddo M., Cuccioloni M., Cecarini V., Eleuteri A.M., Angeletti M. Homology modeling and docking analysis of the interaction between polyphenols and mammalian 20S proteasomes. J Chem Inf Model 2009, 49:401-409.
299. Kitagawa S., Nabekura T., Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KB-C2 cells. J Pharm Pharmacol 2004, 56:1001-1005.
300. Jodoin J., Demeule M., Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002, 1542:149-159.
301. Farabegoli F., Papi A., Bartolini G., Ostan R., Orlandi M. (-)-Epigallocatechin-3-gallate downregulates Pg-P and BCRP in a tamoxifen resistant MCF-7 cell line. Phytomedicine 2010, 17:356-362.
302. Mei Y., Qian F., Wei D., Liu J. Reversal of cancer multidrug resistance by green tea polyphenols. J Pharm Pharmacol 2004, 56:1307-1314.
303. Liang G., Tang A., Lin X., Li L., Zhang S., Huang Z., et al. Green tea catechins augment the antitumor activity of doxorubicin in an in vivo mouse model for chemoresistant liver cancer. Int J Oncol 2010, 37:111-123.
304. Chen T.C., Wang W., Golden E.B., Thomas S., Sivakumar W., Hofman F.M., et al. Green tea epigallocatechin gallate enhances therapeutic efficacy of temozolomide in orthotopic mouse glioblastoma models. Cancer Lett 2011, 302:100-108.
305. Stearns M.E., Amatangelo M.D., Varma D., Sell C., Goodyear S.M. Combination therapy with epigallocatechin-3-gallate and doxorubicin in human prostate tumor modeling studies: inhibition of metastatic tumor growth in severe combined immunodeficiency mice. Am J Pathol 2010, 177:3169-3179.
306. Luo T., Wang J., Yin Y., Hua H., Jing J., Sun X., et al. (-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Res 2010, 12:R8.
307. Davenport A., Frezza M., Shen M., Ge Y., Huo C., Chan T.H., et al. Celastrol and an EGCG pro-drug exhibit potent chemosensitizing activity in human leukemia cells. Int J Mol Med 2010, 25:465-470.
308. Singh M., Bhatnagar P., Srivastava A.K., Kumar P., Shukla Y., Gupta K.C. Enhancement of cancer chemosensitization potential of cisplatin by tea polyphenols poly(lactide-co-glycolide) nanoparticles. J Biomed Nanotechnol 2011, 7:202.
309. Laurie S.A., Miller V.A., Grant S.C., Kris M.G., Ng K.K. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol 2005, 55:33-38.
310. Jatoi A., Ellison N., Burch P.A., Sloan J.A., Dakhil S.R., Novotny P., et al. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 2003, 97:1442-1446.
311. Choan E., Segal R., Jonker D., Malone S., Reaume N., Eapen L., et al. A prospective clinical trial of green tea for hormone refractory prostate cancer: an evaluation of the complementary/alternative therapy approach. Urol Oncol 2005, 23:108-113.
312. Sprouse A.A., Herbert B.S. Resveratrol augments paclitaxel treatment in MDA-MB-231 and paclitaxel-resistant MDA-MB-231 breast cancer cells. Anticancer Res 2014, 34:5363-5374.
313. Huq F., Yu J.Q., Beale P., Chan C., Arzuman L., Nessa M.U., et al. Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer. Anticancer Res 2014, 34:541-545.
314. Chow S.E., Kao C.H., Liu Y.T., Cheng M.L., Yang Y.W., Huang Y.K., et al. Resveratrol induced ER expansion and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma cells. Apoptosis 2014, 19:527-541.
315. Shi X.P., Miao S., Wu Y., Zhang W., Zhang X.F., Ma H.Z., et al. Resveratrol sensitizes tamoxifen in antiestrogen-resistant breast cancer cells with epithelial-mesenchymal transition features. Int J Mol Sci 2013, 14:15655-15668.
316. Lopez P.L., Filippi-Chiela E.C., Silva A.O., Cordero E.A., Garcia-Santos D., Pelegrini A.L., et al. Sensitization of glioma cells by X-linked inhibitor of apoptosis protein knockdown. Oncology 2012, 83:75-82.
317. Diaz-Chavez J., Fonseca-Sanchez M.A., Arechaga-Ocampo E., Flores-Perez A., Palacios-Rodriguez Y., Dominguez-Gomez G., et al. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS ONE 2013, 8:e64378.
318. Farrand L., Byun S., Kim J.Y., Im-aram A., Lee J., Lim S., et al. Piceatannol enhances cisplatin sensitivity in ovarian cancer via modulation of p53, X-linked inhibitor of apoptosis protein (XIAP), and mitochondrial fission. J Biol Chem 2013, 288:23740-23750.
319. Roman V., Billard C., Kern C., Ferry-Dumazet H., Izard J.C., Mohammad R., et al. Analysis of resveratrol-induced apoptosis in human B-cell chronic leukaemia. Br J Haematol 2002, 117:842-851.
320. Billard C., Izard J.C., Roman V., Kern C., Mathiot C., Mentz F., et al. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma 2002, 43:1991-2002.
321. Tomic J., McCaw L., Li Y., Hough M.R., Ben-David Y., Moffat J., et al. Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins. Exp Hematol 2013, 41:675-686.
322. Gokbulut A.A., Apohan E., Baran Y. Resveratrol and quercetin-induced apoptosis of human 232B4 chronic lymphocytic leukemia cells by activation of caspase-3 and cell cycle arrest. Hematology 2013, 18:144-150.
323. Kuttan R., Bhanumathy P., Nirmala K., George M.C. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett 1985, 29:197-202.
324. Gupta S.C., Kismali G., Aggarwal B.B. Curcumin, a component of turmeric: from farm to pharmacy. Biofactors 2013, 39:2-13.
325. Everett P.C., Meyers J.A., Makkinje A., Rabbi M., Lerner A. Preclinical assessment of curcumin as a potential therapy for B-CLL. Am J Hematol 2007, 82:23-30.
326. Hayun R., Okun E., Berrebi A., Shvidel L., Bassous L., Sredni B., et al. Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. Leuk Lymphoma 2009, 50:625-632.
327. Ghosh A.K., Kay N.E., Secreto C.R., Shanafelt T.D. Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 2009, 15:1250-1258.
328. Angelo L.S., Kurzrock R. Turmeric and green tea: a recipe for the treatment of B-chronic lymphocytic leukemia. Clin Cancer Res 2009, 15:1123-1125.
329. Russo M., Spagnuolo C., Tedesco I., Bilotto S., Russo G.L. The flavonoid quercetin in disease prevention and therapy: facts and fancies. Biochem Pharmacol 2012, 83:6-15.
330. Spagnuolo C., Russo M., Bilotto S., Tedesco I., Laratta B., Russo G.L. Dietary polyphenols in cancer prevention: the example of the flavonoid quercetin in leukemia. Ann NY Acad Sci 2012, 1259:95-103.
331. Russo M., Spagnuolo C., Volpe S., Mupo A., Tedesco I., Russo G.L. Quercetin induced apoptosis in association with death receptors and fludarabine in cells isolated from chronic lymphocytic leukaemia patients. Br J Cancer 2010, 103:642-648.
332. Russo M., Spagnuolo C., Volpe S., Tedesco I., Bilotto S., Russo G.L. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation. Biochem Pharmacol 2013, 85:927-936.
333. Okuhashi Y., Itoh M., Nara N., Tohda S. Effects of combination of notch inhibitor plus hedgehog inhibitor or Wnt inhibitor on growth of leukemia cells. Anticancer Res 2011, 31:893-896.
334. Fimognari C., Turrini E., Ferruzzi L., Lenzi M., Hrelia P. Natural isothiocyanates: genotoxic potential versus chemoprevention. Mutat Res 2012, 750:107-131.
335. Fimognari C., Nusse M., Lenzi M., Sciuscio D., Cantelli-Forti G., Hrelia P. Sulforaphane increases the efficacy of doxorubicin in mouse fibroblasts characterized by p53 mutations. Mutat Res 2006, 601:92-101.
336. Geisler S., Lonning P.E., Aas T., Johnsen H., Fluge O., Haugen D.F., et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. Cancer Res 2001, 61:2505-2512.
337. Volkova M., Russell R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev 2011, 7:214-220.
338. Gupta P., Srivastava S.K. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med 2012, 10:80.
339. Garcia R., Yu C.L., Hudnall A., Catlett R., Nelson K.L., Smithgall T., et al. Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. Cell Growth Differ 1997, 8:1267-1276.
340. Kaminski B.M., Weigert A., Brune B., Schumacher M., Wenzel U., Steinhilber D., et al. Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemother Pharmacol 2011, 67:1167-1178.
341. Wang X., Govind S., Sajankila S.P., Mi L., Roy R., Chung F.L. Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin. Mol Nutr Food Res 2011, 55:1572-1581.
342. Lee Y., Kim Y.J., Choi Y.J., Lee J.W., Lee S., Chung H.W. Enhancement of cisplatin cytotoxicity by benzyl isothiocyanate in HL-60 cells. Food Chem Toxicol 2012, 50:2397-2406.
343. Mi L., Wang X., Govind S., Hood B.L., Veenstra T.D., Conrads T.P., et al. The role of protein binding in induction of apoptosis by phenethyl isothiocyanate and sulforaphane in human non-small lung cancer cells. Cancer Res 2007, 67:6409-6416.
344. Mi L., Gan N., Cheema A., Dakshanamurthy S., Wang X., Yang D.C., et al. Cancer preventive isothiocyanates induce selective degradation of cellular alpha- and beta-tubulins by proteasomes. J Biol Chem 2009, 284:17039-17051.
345. Ramalingam S., Belani C.P. Paclitaxel for non-small cell lung cancer. Expert Opin Pharmacother 2004, 5:1771-1780.
346. Hu L., Miao W., Loignon M., Kandouz M., Batist G. Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies. Cancer Chemother Pharmacol 2010, 66:467-474.
347. Nair S., Barve A., Khor T.O., Shen G.X., Lin W., Chan J.Y., et al. Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells. Acta Pharmacol Sin 2010, 31:1223-1240.
348. Slocum S.L., Kensler T.W. Nrf2: control of sensitivity to carcinogens. Arch Toxicol 2011, 85:273-284.
349. Sagar S., Esau L., Holtermann K., Hikmawan T., Zhang G., Stingl U., et al. Induction of apoptosis in cancer cell lines by the Red Sea brine pool bacterial extracts. BMC Complement Altern Med 2013, 13:344.
350. Rengarajan T., Rajendran P., Nandakumar N., Balasubramanian M.P., Nishigaki I. Cancer preventive efficacy of marine carotenoid fucoxanthin: cell cycle arrest and apoptosis. Nutrients 2013, 5:4978-4989.
351. Farnaes L., Coufal N.G., Kauffman C.A., Rheingold A.L., DiPasquale A.G., Jensen P.R., et al. Napyradiomycin derivatives, produced by a marine-derived actinomycete, illustrate cytotoxicity by induction of apoptosis. J Nat Prod 2014, 77:15-21.
352. Farnaes L., La Clair J.J., Fenical W. Napyradiomycins CNQ525.510B and A80915C target the Hsp90 paralogue Grp94. Org Biomol Chem 2014, 12:418-423.
353. Haste N.M., Farnaes L., Perera V.R., Fenical W., Nizet V., Hensler M.E. Bactericidal kinetics of marine-derived napyradiomycins against contemporary methicillin-resistant Staphylococcus aureus. Mar Drugs 2011, 9:680-689.
354. Kumar S.R., Hosokawa M., Miyashita K. Fucoxanthin: a marine carotenoid exerting anti-cancer effects by affecting multiple mechanisms. Mar Drugs 2013, 11:5130-5147.
355. Nguyen V.T., Lee J.S., Qian Z.J., Li Y.X., Kim K.N., Heo S.J., et al. Gliotoxin isolated from marine fungus Aspergillus sp. induces apoptosis of human cervical cancer and chondrosarcoma cells. Mar Drugs 2014, 12:69-87.
356. Garcia-Caballero M., Canedo L., Fernandez-Medarde A., Medina M.A., Quesada A.R. The marine fungal metabolite, AD0157, inhibits angiogenesis by targeting the Akt signaling pathway. Mar Drugs 2014, 12:279-299.
357. Garcia-Caballero M., Mari-Beffa M., Canedo L., Medina M.A., Quesada A.R. Toluquinol, a marine fungus metabolite, is a new angiosuppresor that interferes with the Akt pathway. Biochem Pharmacol 2013, 85:1727-1740.
358. Goncalves A.M., de Lima A.B., da Silva Barbosa M.C., de Camargos L.F., de Oliveira J.T., de Souza B.C., et al. Synthesis and biological evaluation of novel 3-alkylpyridine marine alkaloid analogs with promising anticancer activity. Mar Drugs 2014, 12:4361-4378.
359. Beesoo R., Neergheen-Bhujun V., Bhagooli R., Bahorun T. Apoptosis inducing lead compounds isolated from marine organisms of potential relevance in cancer treatment. Mutat Res Fundam Mol Mech Mutagen 2014, 10.1016/j.mrfmmm.2014.03.005.
360. Yin Y., Chen X., Zhang C.D., Liu P.F., Duan Y.R., Fan Y.R., et al. Asymmetric siRNA targeting the bcl2 gene inhibits the proliferation of cancer cells in vitro and in vivo. Int J Oncol 2013, 42:253-260.
361. Zhen Y., Liu Z., Yang H., Yu X., Wu Q., Hua S., et al. Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis 2013, 4:e872.
362. Bolesta E., Pfannenstiel L.W., Demelash A., Lesniewski M.L., Tobin M., Schlanger S.E., et al. Inhibition of Mcl-1 promotes senescence in cancer cells: implications for preventing tumor growth and chemotherapy resistance. Mol Cell Biol 2012, 32:1879-1892.
363. Chen N., Eritja N., Lock R., Debnath J. Autophagy restricts proliferation driven by oncogenic phosphatidylinositol 3-kinase in three-dimensional culture. Oncogene 2013, 32:2543-2554.
364. Kaminskyy V.O., Piskunova T., Zborovskaya I.B., Tchevkina E.M., Zhivotovsky B. Suppression of basal autophagy reduces lung cancer cell proliferation and enhances caspase-dependent and -independent apoptosis by stimulating ROS formation. Autophagy 2012, 8:1032-1044.
365. Sha W., Olesch C., Hanaka H., Radmark O., Weigert A., Brune B. Necrosis in DU145 prostate cancer spheroids induces COX-2/mPGES-1-derived PGE2 to promote tumor growth and to inhibit T cell activation. Int J Cancer 2013, 133:1578-1588.
366. Dutta S., Going J.J., Crumley A.B., Mohammed Z., Orange C., Edwards J., et al. The relationship between tumour necrosis, tumour proliferation, local and systemic inflammation, microvessel density and survival in patients undergoing potentially curative resection of oesophageal adenocarcinoma. Br J Cancer 2012, 106:702-710.
367. Chang D.J., An H., Kim K.S., Kim H.H., Jung J., Lee J.M., et al. Design, synthesis, and biological evaluation of novel deguelin-based heat shock protein 90 (HSP90) inhibitors targeting proliferation and angiogenesis. J Med Chem 2012, 55:10863-10884.
368. Zhao M., Ma J., Zhu H.Y., Zhang X.H., Du Z.Y., Xu Y.J., et al. Apigenin inhibits proliferation and induces apoptosis in human multiple myeloma cells through targeting the trinity of CK2, Cdc37 and Hsp90. Mol Cancer 2011, 10:104.
369. Hui B., Shi Y.H., Ding Z.B., Zhou J., Gu C.Y., Peng Y.F., et al. Proteasome inhibitor interacts synergistically with autophagy inhibitor to suppress proliferation and induce apoptosis in hepatocellular carcinoma. Cancer 2012, 118:5560-5571.
370. Bono C., Karlin L., Harel S., Mouly E., Labaume S., Galicier L., et al. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica 2012, 97:1101-1109.
371. Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ 2012, 19:67-74.
372. Hsu A., Bruno R.S., Lohr C.V., Taylor A.W., Dashwood R.H., Bray T.M., et al. Dietary soy and tea mitigate chronic inflammation and prostate cancer via NFkappaB pathway in the Noble rat model. J Nutr Biochem 2011, 22:502-510.
373. Zhang H.Y., Zhang Q., Zhang X., Yu C., Huo X., Cheng E., et al. Cancer-related inflammation and Barrett's carcinogenesis: interleukin-6 and STAT3 mediate apoptotic resistance in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol 2011, 300:G454-G460.
374. Chen L.S., Balakrishnan K., Gandhi V. Inflammation and survival pathways: chronic lymphocytic leukemia as a model system. Biochem Pharmacol 2010, 80:1936-1945.
375. Chang C.P., Su Y.C., Lee P.H., Lei H.Y. Targeting NFKB by autophagy to polarize hepatoma-associated macrophage differentiation. Autophagy 2013, 9:619-621.
376. Liu E.Y., Ryan K.M. Autophagy and cancer - issues we need to digest. J Cell Sci 2012, 125:2349-2358.
377. Chopra M., Lang I., Salzmann S., Pachel C., Kraus S., Bauerlein C.A., et al. Tumor necrosis factor induces tumor promoting and anti-tumoral effects on pancreatic cancer via TNFR1. PLoS ONE 2013, 8:e75737.
378. Snow B.J., Peppard R.F., Guttman M., Okada J., Martin W.R., Steele J., et al. Positron emission tomographic scanning demonstrates a presynaptic dopaminergic lesion in Lytico-Bodig. The amyotrophic lateral sclerosis-parkinsonism-dementia complex of Guam. Arch Neurol 1990, 47:870-874.
379. Du Y., Moulick K., Rodina A., Aguirre J., Felts S., Dingledine R., et al. High-throughput screening fluorescence polarization assay for tumor-specific Hsp90. J Biomol Screen 2007, 12:915-924.
380. Arthur J.C., Lich J.D., Aziz R.K., Kotb M., Ting J.P. Heat shock protein 90 associates with monarch-1 and regulates its ability to promote degradation of NF-kappaB-inducing kinase. J Immunol 2007, 179:6291-6296.
381. Cortes Sempere M., Rodriguez Fanjul V., Sanchez Perez I., Perona R. The role of the NFkappaB signalling pathway in cancer. Clin Transl Oncol: Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mexico 2008, 10:143-147.
382. Dalla Via L., Nardon C., Fregona D. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Fut Med Chem 2012, 4:525-543.
383. Op den Kamp C.M., Langen R.C., Minnaard R., Kelders M.C., Snepvangers F.J., Hesselink M.K., et al. Pre-cachexia in patients with stages I-III non-small cell lung cancer: systemic inflammation and functional impairment without activation of skeletal muscle ubiquitin proteasome system. Lung Cancer 2012, 76:112-117.
384. Deng J., Shimamura T., Perera S., Carlson N.E., Cai D., Shapiro G.I., et al. Proapoptotic BH3-only BCL-2 family protein BIM connects death signaling from epidermal growth factor receptor inhibition to the mitochondrion. Cancer Res 2007, 67:11867-11875.
385. Cai J., Ahmad S., Jiang W.G., Huang J., Kontos C.D., Boulton M., et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 2003, 52:2959-2968.
386. Trisciuoglio D., Iervolino A., Zupi G., Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005, 16:4153-4162.
387. Chandra A., Lan S., Zhu J., Siclari V.A., Qin L. Epidermal growth factor receptor (EGFR) signaling promotes proliferation and survival in osteoprogenitors by increasing early growth response 2 (EGR2) expression. J Biol Chem 2013, 288:20488-20498.
388. Chen S., Han Q., Wang X., Yang M., Zhang Z., Li P., et al. IBP-mediated suppression of autophagy promotes growth and metastasis of breast cancer cells via activating mTORC2/Akt/FOXO3a signaling pathway. Cell Death Dis 2013, 4:e842.
389. Nakagami H., Cui T.X., Iwai M., Shiuchi T., Takeda-Matsubara Y., Wu L., et al. Tumor necrosis factor-alpha inhibits growth factor-mediated cell proliferation through SHP-1 activation in endothelial cells. Arterioscler Thromb Vasc Biol 2002, 22:238-242.
390. Chandarlapaty S., Scaltriti M., Angelini P., Ye Q., Guzman M., Hudis C.A., et al. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 2010, 29:325-334.
391. Duval M., Le Boeuf F., Huot J., Gratton J.P. Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase. Mol Biol Cell 2007, 18:4659-4668.
392. Yang Y., Ikezoe T., Saito T., Kobayashi M., Koeffler H.P., Taguchi H. Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci 2004, 95:176-180.
393. Cascone T., Morelli M.P., Morgillo F., Kim W.Y., Rodolico G., Pepe S., et al. Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. J Cell Physiol 2008, 216:698-707.
394. Alt J.R., Cleveland J.L., Hannink M., Diehl J.A. Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 2000, 14:3102-3114.
395. Johnson V.L., Cooper I.R., Jenkins J.R., Chow S.C. Effects of differential overexpression of Bcl-2 on apoptosis, proliferation, and telomerase activity in Jurkat T cells. Exp Cell Res 1999, 251:175-184.
396. Mandal M., Kumar R. Bcl-2 modulates telomerase activity. J Biol Chem 1997, 272:14183-14187.
397. Aoki H., Iwado E., Eller M.S., Kondo Y., Fujiwara K., Li G.Z., et al. Telomere 3' overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells. FASEB J 2007, 21:2918-2930.
398. Iwado E., Daido S., Kondo Y., Kondo S. Combined effect of 2-5A-linked antisense against telomerase RNA and conventional therapies on human malignant glioma cells in vitro and in vivo. Int J Oncol 2007, 31:1087-1095.
399. Capparelli C., Guido C., Whitaker-Menezes D., Bonuccelli G., Balliet R., Pestell T.G., et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle (Georgetown, Tex) 2012, 11:2285-2302.
400. Jain M.V., Paczulla A.M., Klonisch T., Dimgba F.N., Rao S.B., Roberg K., et al. Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J Cell Mol Med 2013, 17:12-29.
401. Restall I.J., Lorimer I.A. Induction of premature senescence by hsp90 inhibition in small cell lung cancer. PLoS ONE 2010, 5:e11076.
402. Chan K.C., Ting C.M., Chan P.S., Lo M.C., Lo K.W., Curry J.E., et al. A novel Hsp90 inhibitor AT13387 induces senescence in EBV-positive nasopharyngeal carcinoma cells and suppresses tumor formation. Mol Cancer 2013, 12:128.
403. Torres C.A., Perez V.I. Proteasome modulates mitochondrial function during cellular senescence. Free Radic Biol Med 2008, 44:403-414.
404. Chondrogianni N., Stratford F.L., Trougakos I.P., Friguet B., Rivett A.J., Gonos E.S. Central role of the proteasome in senescence and survival of human fibroblasts: induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem 2003, 278:28026-28037.
405. Hu T., Zhang C., Tang Q., Su Y., Li B., Chen L., et al. Variant G6PD levels promote tumor cell proliferation or apoptosis via the STAT3/5 pathway in the human melanoma xenograft mouse model. BMC Cancer 2013, 13:251.
406. Chio C.C., Lin J.W., Cheng H.A., Chiu W.T., Wang Y.H., Wang J.J., et al. MicroRNA-210 targets antiapoptotic Bcl-2 expression and mediates hypoxia-induced apoptosis of neuroblastoma cells. Arch Toxicol 2013, 87:459-468.
407. MacFarlane M., Robinson G.L., Cain K. Glucose - a sweet way to die: metabolic switching modulates tumor cell death. Cell Cycle (Georgetown, Tex) 2012, 11:3919-3925.
408. Kim S.M., Yun M.R., Hong Y.K., Solca F., Kim J.H., Kim H.J., et al. Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol Cancer Ther 2013, 12:2145-2156.
409. Choi H.N., Jin H.O., Kim J.H., Hong S.E., Kim H.A., Kim E.K., et al. Inhibition of S6K1 enhances glucose deprivation-induced cell death via downregulation of anti-apoptotic proteins in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2013, 432:123-128.
410. McBrayer S.K., Cheng J.C., Singhal S., Krett N.L., Rosen S.T., Shanmugam M. Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 2012, 119:4686-4697.
411. Pal K., Cao Y., Gaisina I.N., Bhattacharya S., Dutta S.K., Wang E., et al. Inhibition of GSK-3 induces differentiation and impaired glucose metabolism in renal cancer. Mol Cancer Ther 2014, 13:285-296.
412. Rosenfeldt M.T., O'Prey J., Morton J.P., Nixon C., MacKay G., Mrowinska A., et al. p53 status determines the role of autophagy in pancreatic tumour development. Nature 2013, 504:296-300.
413. Klarer A.C., O'Neal J., Imbert-Fernandez Y., Clem A., Ellis S.R., Clark J., et al. Inhibition of 6-phosphofructo-2-kinase (PFKFB3) induces autophagy as a survival mechanism. Cancer Metab 2014, 2:2.
414. Wanka C., Brucker D.P., Bahr O., Ronellenfitsch M., Weller M., Steinbach J.P., et al. Synthesis of cytochrome C oxidase 2: a p53-dependent metabolic regulator that promotes respiratory function and protects glioma and colon cancer cells from hypoxia-induced cell death. Oncogene 2012, 31:3764-3776.
415. Qin J.Z., Xin H., Nickoloff B.J. 2-deoxyglucose sensitizes melanoma cells to TRAIL-induced apoptosis which is reduced by mannose. Biochem Biophys Res Commun 2010, 401:293-299.
416. Pradelli L.A., Beneteau M., Chauvin C., Jacquin M.A., Marchetti S., Munoz-Pinedo C., et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 2010, 29:1641-1652.
417. Wood T.E., Dalili S., Simpson C.D., Hurren R., Mao X., Saiz F.S., et al. A novel inhibitor of glucose uptake sensitizes cells to FAS-induced cell death. Mol Cancer Ther 2008, 7:3546-3555.
418. Mayer P., Harjung A., Breinig M., Fischer L., Ehemann V., Malz M., et al. Expression and therapeutic relevance of heat-shock protein 90 in pancreatic endocrine tumors. Endocr Relat Cancer 2012, 19:217-232.
419. Beck R., Verrax J., Gonze T., Zappone M., Pedrosa R.C., Taper H., et al. Hsp90 cleavage by an oxidative stress leads to its client proteins degradation and cancer cell death. Biochem Pharmacol 2009, 77:375-383.
420. Tsuruo T., Naito M., Tomida A., Fujita N., Mashima T., Sakamoto H., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21.
421. Busacca S., Chacko A.D., Klabatsa A., Arthur K., Sheaff M., Barbone D., et al. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. PLoS ONE 2013, 8:e65489.
422. Zheng J.M., Wang D.K., Jiang H.M. bcl-2 expression in small cell lung cancer: a mechanism for apoptosis antagonism and immune evasion. Di 1 Jun Yi Da Xue Xue Bao = Acad J First Med Coll PLA 2005, 25:1537-1539.
423. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004, 8:409-422.
424. Kareva I., Hahnfeldt P. The emerging hallmarks of metabolic reprogramming and immune evasion: distinct or linked. Cancer Res 2013, 73:2737-2742.
425. Niebler M., Qian X., Hofler D., Kogosov V., Kaewprag J., Kaufmann A.M., et al. Post-translational control of IL-1beta via the human papillomavirus type 16 E6 oncoprotein: a novel mechanism of innate immune escape mediated by the E3-ubiquitin ligase E6-AP and p53. PLoS Pathogens 2013, 9:e1003536.
426. Zhang X., Dawson C.W., He Z., Huang P. Immune evasion strategies of the human gamma-herpesviruses: implications for viral tumorigenesis. J Med Virol 2012, 84:272-281.
427. Ayshamgul H., Ma H., Ilyar S., Zhang L.W., Abulizi A. Association of defective HLA-I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chin Med J (Engl) 2011, 124:341-346.
428. Nor J.E., Christensen J., Liu J., Peters M., Mooney D.J., Strieter R.M., et al. Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 2001, 61:2183-2188.
429. Pignochino Y., Grignani G., Cavalloni G., Motta M., Tapparo M., Bruno S., et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer 2009, 8:118.
430. Hippert M.M., O'Toole P.S., Thorburn A. Autophagy in cancer: good, bad, or both. Cancer Res 2006, 66:9349-9351.
431. Edwards J.G., Swinson D.E., Jones J.L., Muller S., Waller D.A., O'Byrne K.J. Tumor necrosis correlates with angiogenesis and is a predictor of poor prognosis in malignant mesothelioma. Chest 2003, 124:1916-1923.
432. Sun J., Liao J.K. Induction of angiogenesis by heat shock protein 90 mediated by protein kinase Akt and endothelial nitric oxide synthase. Arterioscler Thromb Vasc Biol 2004, 24:2238-2244.
433. Oikawa T., Sasaki T., Nakamura M., Shimamura M., Tanahashi N., Omura S., et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998, 246:243-248.
434. Knauer S.K., Kramer O.H., Knosel T., Engels K., Rodel F., Kovacs A.F., et al. Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J 2007, 21:207-216.
435. Zuo J., Ishikawa T., Boutros S., Xiao Z., Humtsoe J.O., Kramer R.H. Bcl-2 overexpression induces a partial epithelial to mesenchymal transition and promotes squamous carcinoma cell invasion and metastasis. Mol Cancer Res: MCR 2010, 8:170-182.
436. Likui W., Qun L., Wanqing Z., Haifeng S., Fangqiu L., Xiaojun L. Prognostic role of myeloid cell leukemia-1 protein (Mcl-1) expression in human gastric cancer. J Surg Oncol 2009, 100:396-400.
437. Lv Q., Wang W., Xue J., Hua F., Mu R., Lin H., et al. DEDD interacts with PI3KC3 to activate autophagy and attenuate epithelial-mesenchymal transition in human breast cancer. Cancer Res 2012, 72:3238-3250.
438. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., et al. Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell 2006, 10:51-64.
439. Seki N., Hayakawa Y., Brooks A.D., Wine J., Wiltrout R.H., Yagita H., et al. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis is an important endogenous mechanism for resistance to liver metastases in murine renal cancer. Cancer Res 2003, 63:207-213.
440. Koga F., Kihara K., Neckers L. Inhibition of cancer invasion and metastasis by targeting the molecular chaperone heat-shock protein 90. Anticancer Res 2009, 29:797-807.
441. Yan W., Xiao J., Liu T., Huang W., Yang X., Wu Z., et al. The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma. Tumour Biol 2013, 34:1391-1397.
442. Zhu S., Yao F., Li W.H., Wan J.N., Zhang Y.M., Tang Z., et al. PKC?-dependent activation of the ubiquitin proteasome system is responsible for high glucose-induced human breast cancer MCF-7 cell proliferation, migration and invasion. Asian Pac J Cancer Prevent: APJCP 2013, 14:5687-5692.
443. Inoue H., Kauffman M., Shacham S., Landesman Y., Yang J., Evans C.P., et al. CRM1 blockade by selective inhibitors of nuclear export attenuates kidney cancer growth. J Urol 2013, 189:2317-2326.
444. Buggins A.G., Pepper C., Patten P.E., Hewamana S., Gohil S., Moorhead J., et al. Interaction with vascular endothelium enhances survival in primary chronic lymphocytic leukemia cells via NF-kappaB activation and de novo gene transcription. Cancer Res 2010, 70:7523-7533.
445. Anai S., Sakamoto N., Sakai Y., Tanaka M., Porvasnik S., Urbanek C., et al. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer. Urol Oncol 2011, 29:421-429.
446. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., et al. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
447. Zhu H., Wang D., Liu Y., Su Z., Zhang L., Chen F., et al. Role of the Hypoxia-inducible factor-1 alpha induced autophagy in the conversion of non-stem pancreatic cancer cells into CD133+ pancreatic cancer stem-like cells. Cancer Cell Int 2013, 13:119.
448. Mo J., Sun B., Zhao X., Gu Q., Dong X., Liu Z., et al. Hypoxia-induced senescence contributes to the regulation of microenvironment in melanomas. Pathol Res Pract 2013, 209:640-647.
449. Walsby E., Pearce L., Burnett A.K., Fegan C., Pepper C. The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells. Oncotarget 2012, 3:525-534.
450. Skandalis S.S., Aletras A.J., Gialeli C., Theocharis A.D., Afratis N., Tzanakakis G.N., et al. Targeting the tumor proteasome as a mechanism to control the synthesis and bioactivity of matrix macromolecules. Curr Mol Med 2012, 12:1068-1082.
451. Tai Y.T., Landesman Y., Acharya C., Calle Y., Zhong M.Y., Cea M., et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia 2014, 28:155-165.
452. Valenti D., de Bari L., Manente G.A., Rossi L., Mutti L., Moro L., et al. Negative modulation of mitochondrial oxidative phosphorylation by epigallocatechin-3 gallate leads to growth arrest and apoptosis in human malignant pleural mesothelioma cells. Biochim Biophys Acta 2013, 1832:2085-2096.
453. Zhang Q., Fu H., Pan J., He J., Ryota S., Hara Y., et al. Effect of dietary Polyphenon E and EGCG on lung tumorigenesis in A/J Mice. Pharm Res 2010, 27:1066-1071.
454. Pang X., Wu Y., Wu Y., Lu B., Chen J., Wang J., et al. (-)-Gossypol suppresses the growth of human prostate cancer xenografts via modulating VEGF signaling-mediated angiogenesis. Mol Cancer Ther 2011, 10:795-805.
455. Zhang X.Q., Huang X.F., Mu S.J., An Q.X., Xia A.J., Chen R., et al. Inhibition of proliferation of prostate cancer cell line, PC-3, in vitro and in vivo using (-)-gossypol. Asian J Androl 2010, 12:390-399.
456. Deng Y.T., Lin J.K. EGCG inhibits the invasion of highly invasive CL1-5 lung cancer cells through suppressing MMP-2 expression via JNK signaling and induces G2/M arrest. J Agric Food Chem 2011, 59:13318-13327.
457. Wang H., Bian S., Yang C.S. Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1alpha. Carcinogenesis 2011, 32:1881-1889.
458. Liu J., Shen M., Yue Z., Yang Z., Wang M., Li C., et al. Triptolide inhibits colon-rectal cancer cells proliferation by induction of G1 phase arrest through upregulation of p21. Phytomedicine 2012, 19:756-762.
459. Zhao F., Huang W., Ousman T., Zhang B., Han Y., Clotaire D.Z., et al. Triptolide induces growth inhibition and apoptosis of human laryngocarcinoma cells by enhancing p53 activities and suppressing E6-mediated p53 degradation. PLoS ONE 2013, 8:e80784.
460. Wang J., Jin L., Li X., Deng H., Chen Y., Lian Q., et al. Gossypol induces apoptosis in ovarian cancer cells through oxidative stress. Mol BioSyst 2013, 9:1489-1497.
461. Soderquist R., Bates D.J., Danilov A.V., Eastman A. Gossypol overcomes stroma-mediated resistance to the BCL2 inhibitor ABT-737 in chronic lymphocytic leukemia cells ex vivo. Leukemia 2013, 27:2262-2264.
462. Hardtner C., Multhoff G., Falk W., Radons J. (-)-Epigallocatechin-3-gallate, a green tea-derived catechin, synergizes with celecoxib to inhibit IL-1-induced tumorigenic mediators by human pancreatic adenocarcinoma cells Colo357. Eur J Pharmacol 2012, 684:36-43.
463. Hoffmann J., Junker H., Schmieder A., Venz S., Brandt R., Multhoff G., et al. EGCG downregulates IL-1RI expression and suppresses IL-1-induced tumorigenic factors in human pancreatic adenocarcinoma cells. Biochem Pharmacol 2011, 82:1153-1162.
464. Park B., Sung B., Yadav V.R., Chaturvedi M.M., Aggarwal B.B. Triptolide, histone acetyltransferase inhibitor, suppresses growth and chemosensitizes leukemic cells through inhibition of gene expression regulated by TNF-TNFR1-TRADD-TRAF2-NIK-TAK1-IKK pathway. Biochem Pharmacol 2011, 82:1134-1144.
465. Pan J. RNA polymerase - an important molecular target of triptolide in cancer cells. Cancer Lett 2010, 292:149-152.
466. Jiang J., Ye W., Lin Y.C. Gossypol inhibits the growth of MAT-LyLu prostate cancer cells by modulation of TGFbeta/Akt signaling. Int J Mol Med 2009, 24:69-75.
467. Jiang J., Sugimoto Y., Liu S., Chang H.L., Park K.Y., Kulp S.K., et al. The inhibitory effects of gossypol on human prostate cancer cells-PC3 are associated with transforming growth factor beta1 (TGFbeta1) signal transduction pathway. Anticancer Res 2004, 24:91-100.
468. Chang C.M., Chang P.Y., Tu M.G., Lu C.C., Kuo S.C., Amagaya S., et al. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2. Oncol Rep 2012, 28:1799-1807.
469. Hsu Y.C., Liou Y.M. The anti-cancer effects of (-)-epigallocatechin-3-gallate on the signaling pathways associated with membrane receptors in MCF-7 cells. J Cell Physiol 2011, 226:2721-2730.
470. Hwang K.C., Lee K.H., Jang Y., Yun Y.P., Chung K.H. Epigallocatechin-3-gallate inhibits basic fibroblast growth factor-induced intracellular signaling transduction pathway in rat aortic smooth muscle cells. J Cardiovasc Pharmacol 2002, 39:271-277.
471. Huang W., He T., Chai C., Yang Y., Zheng Y., Zhou P., et al. Triptolide inhibits the proliferation of prostate cancer cells and down-regulates SUMO-specific protease 1 expression. PLoS ONE 2012, 7:e37693.
472. Sahin F., Avci C.B., Gunduz C., Sezgin C., Simsir I.Y., Saydam G. Gossypol exerts its cytotoxic effect on HL-60 leukemic cell line via decreasing activity of protein phosphatase 2A and interacting with human telomerase reverse transcriptase activity. Hematology 2010, 15:144-150.
473. Moon D.O., Kim M.O., Choi Y.H., Lee H.G., Kim N.D., Kim G.Y. Gossypol suppresses telomerase activity in human leukemia cells via regulating hTERT. FEBS Lett 2008, 582:3367-3373.
474. Wang X., Hao M.W., Dong K., Lin F., Ren J.H., Zhang H.Z. Apoptosis induction effects of EGCG in laryngeal squamous cell carcinoma cells through telomerase repression. Arch Pharmacal Res 2009, 32:1263-1269.
475. Berletch J.B., Liu C., Love W.K., Andrews L.G., Katiyar S.K., Tollefsbol T.O. Epigenetic and genetic mechanisms contribute to telomerase inhibition by EGCG. J Cell Biochem 2008, 103:509-519.
476. Kiviharju T.M., Lecane P.S., Sellers R.G., Peehl D.M. Antiproliferative and proapoptotic activities of triptolide (PG490), a natural product entering clinical trials, on primary cultures of human prostatic epithelial cells. Clin Cancer Res 2002, 8:2666-2674.
477. Schwartz P.S., Manion M.K., Emerson C.B., Fry J.S., Schulz C.M., Sweet I.R., et al. 2-Methoxy antimycin reveals a unique mechanism for Bcl-x(L) inhibition. Mol Cancer Ther 2007, 6:2073-2080.
478. Huang K.H., Kuo K.L., Chen S.C., Weng T.I., Chuang Y.T., Tsai Y.C., et al. Down-regulation of glucose-regulated protein (GRP) 78 potentiates cytotoxic effect of celecoxib in human urothelial carcinoma cells. PLoS ONE 2012, 7:e33615.
479. Tan B.J., Chiu G.N. Role of oxidative stress, endoplasmic reticulum stress and ERK activation in triptolide-induced apoptosis. Int J Oncol 2013, 42:1605-1612.
480. Chen L., Liu Q., Huang Z., Wu F., Li Z., Chen X., et al. Tripchlorolide induces cell death in lung cancer cells by autophagy. Int J Oncol 2012, 40:1066-1070.
481. Wu P.P., Liu K.C., Huang W.W., Ma C.Y., Lin H., Yang J.S., et al. Triptolide induces apoptosis in human adrenal cancer NCI-H295 cells through a mitochondrial-dependent pathway. Oncol Rep 2011, 25:551-557.
482. Tarnow J. Art and pitfalls of preoperative anesthesia information. Anasthesiol Intens Notfallmed Schmerzther: AINS 1999, 34:723-724.
483. Jang J.Y., Lee J.K., Jeon Y.K., Kim C.W. Exosome derived from epigallocatechin gallate treated breast cancer cells suppresses tumor growth by inhibiting tumor-associated macrophage infiltration and M2 polarization. BMC Cancer 2013, 13:421.
484. Liang M., Fu J. Triptolide inhibits interferon-gamma-induced programmed death-1-ligand 1 surface expression in breast cancer cells. Cancer Lett 2008, 270:337-341.
485. Shankar S., Ganapathy S., Hingorani S.R., Srivastava R.K. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008, 13:440-452.
486. Ma J.X., Sun Y.L., Wang Y.Q., Wu H.Y., Jin J., Yu X.F. Triptolide induces apoptosis and inhibits the growth and angiogenesis of human pancreatic cancer cells by downregulating COX-2 and VEGF. Oncol Res 2013, 20:359-368.
487. Wolter K.G., Wang S.J., Henson B.S., Wang S., Griffith K.A., Kumar B., et al. (-)-gossypol inhibits growth and promotes apoptosis of human head and neck squamous cell carcinoma in vivo. Neoplasia 2006, 8:163-172.
488. Brohem C.A., Massaro R.R., Tiago M., Marinho C.E., Jasiulionis M.G., de Almeida R.L., et al. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death. Pigment Cell Melanoma Res 2012, 25:354-369.
489. Yang S., Chen J., Guo Z., Xu X.M., Wang L., Pei X.F., et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003, 2:65-72.
490. Pacak K., Sirova M., Giubellino A., Lencesova L., Csaderova L., Laukova M., et al. NF-kappaB inhibition significantly upregulates the norepinephrine transporter system, causes apoptosis in pheochromocytoma cell lines and prevents metastasis in an animal model. Int J Cancer 2012, 131:2445-2455.
491. Cheng Y., Holloway M.P., Nguyen K., McCauley D., Landesman Y., Kauffman M.G., et al. XPO1 (CRM1) inhibition represses STAT3 activation to drive a survivin-dependent oncogenic switch in triple-negative breast cancer. Mol Cancer Ther 2014, 13:675-686.
492. Etchin J., Sanda T., Mansour M.R., Kentsis A., Montero J., Le B.T., et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol 2013, 161:117-127.
493. Voss V., Senft C., Lang V., Ronellenfitsch M.W., Steinbach J.P., Seifert V., et al. The pan-Bcl-2 inhibitor (-)-gossypol triggers autophagic cell death in malignant glioma. Mol Cancer Res: MCR 2010, 8:1002-1016.
494. Zgheib A., Lamy S., Annabi B. Epigallocatechin gallate targeting of membrane type 1 matrix metalloproteinase-mediated Src and Janus kinase/signal transducers and activators of transcription 3 signaling inhibits transcription of colony-stimulating factors 2 and 3 in mesenchymal stromal cells. J Biol Chem 2013, 288:13378-13386.
495. Hung F.M., Chen Y.L., Huang A.C., Hsiao Y.P., Yang J.S., Chung M.T., et al. Triptolide induces S phase arrest via the inhibition of cyclin E and CDC25A and triggers apoptosis via caspase- and mitochondrial-dependent signaling pathways in A375.S2 human melanoma cells. Oncol Rep 2013, 29:1053-1060.
496. Carter B.Z., Mak D.H., Shi Y., Fidler J.M., Chen R., Ling X., et al. MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia 2012, 26:443-450.
497. Zhong Y., El-Gamal D., Dubovsky J.A., Beckwith K.A., Harrington B.K., Williams K.E., et al. Selinexor suppresses downstream effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells. Leukemia 2014, 28:1158-1163.